Cite
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors
MLA
Deodhar, Atul, et al. Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. Jan. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid.dedup....8d8d7a5e184949acfb564f0b9af9b4f6&authtype=sso&custid=ns315887.
APA
Deodhar, A., Poddubnyy, D., Pacheco, T. C., Salvarani, C., Lespessailles, E., Rahman, P., Järvinen, P., Sanchez, B. J., Gaffney, K., Lee, E. B., Krishnan, E., Santisteban, S., Li, X., Zhao, F., Carlier, H., Reveille, J., Antolini, C., Azevedo, V., Barkham, M., … Zisman, D. (2019). Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.
Chicago
Deodhar, Atul, Denis Poddubnyy, Tena, Cesar Pacheco, Carlo Salvarani, Eric Lespessailles, Proton Rahman, Pentti Järvinen, et al. 2019. “Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid.dedup....8d8d7a5e184949acfb564f0b9af9b4f6&authtype=sso&custid=ns315887.